©2010–2020 Apsis Therapeutics, INC. All rights reserved.

APSIS Strategies for Cure:
Our developing pipelines are focused on Human immunodeficiency virus (HIV) , Hepatitis B, Herpes simplex (HSV), and other viral infectious diseases. Our antiviral therapeutic strategies are directed at eradicating viral nucleic acids by terminating their synthesis and facilitating their eliminations to cure latent and/or chronic viral infectious diseases.

1. Terminating viral enzymatic synthesis of nucleic acids:

HIV Reverse Transcriptase Inhibitors

HBV Polymerase Inhibitors

2. Eliminating viral nucleic acids:

Viral DNA cleaving oligonucleotides-protein complexes (Cas9-lgRNA^TM ):

Apsis Discovery Platforms:

1. Our lead programs target viral DNA and RNA synthesis by developing selective inhibitors of  nucleoside and nucleotide analogues. The biological targets include HIV reverse transcriptase, HBV polymerase, and other viral DNA polymerases.

2. We develop nucleotide prodrugs for better drug properties and bypassing the first phosphorylation as a limiting activation step, based on nucleotide prodrugs as antiviral agents for cell-selective delivery and bypassing drug efflux proteins. 

3. Based on APSIS proprietary lgRNA technology, we engineer CRISPR-Cas9 (Cas9-lgRNA^TM) to remove viral DNAs for cure.